The market authorisation for Zubrin has been withdrawn at the request of the marketing-authorisation holder.
Zubrin : EPAR - Summary for the public (PDF/510.23 KB)
First published: 23/05/2006
Last updated: 08/05/2012
|Agency product number||
|International non-proprietary name (INN) or common name||
|Anatomical therapeutic chemical veterinary (ATCvet) codes||
Intervet International B. V.
|Date of issue of marketing authorisation valid throughout the European Union||
02/02/2012 Zubrin - EMEA/V/C/000057 - IB/0032
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Reduction of inflammation and relief of pain caused by acute and chronic musculoskeletal disorders.